LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients ( N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease ( n = 74), TEAEs ( n = 19), and other reasons ( n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Management of relapsed MM remains challenging; patients are becoming triple-class exposed (TCE) earlier in their treatment course, 4-8 with no standard of care for early TCE relapsed and refractory MM (R/RMM).”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“with a response in 29.8% and median overall survival of 12.4 months. 8”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with triple-class-refractory multiple myeloma (i.e., disease that is refractory to a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody) or relapsed multiple myeloma who receive standard treatment have a poor prognosis, with a response in 29.8% and median overall survival of 12.4 months. 8”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“with a response in 29.8% and median overall survival of 12.4 months. 8”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Prognosis is poor with conventional therapies, with a median progression-free survival (PFS) of ~3 to 5 months and a median overall survival (OS) of ~9 to 22 months in this patient population. 5-12”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [7]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Self-citationKumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351 · cited 1×
“These data are consistent with several retrospective studies in heavily pretreated patients with RRMM, including the MAMMOTH study, that have generally shown low OS rates and rapid disease progression [3, 7, 8].”
ResultSelf-citationUsmani, S., Ahmadi, T., Ng, Y., Lam, A., Desai, A., Potluri, R., & Mehra, M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0104 · Cited by 139
Ravi, P. K., Kumar, S. K., Cerhan, J. R., Maurer, M. J., Dingli, D., Ansell, S. M., & Rajkumar, S. V. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0065-8 · Cited by 133
Immunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 68
Clarification of the definition of complete response in multiple myeloma
Durie, B. G. M., Miguel, J. F. S., Blade, J., Rajkumar, S. V., & on behalf of the International Myeloma Working Group (2015) · Leukemia · doi:10.1038/leu.2015.290 · Cited by 42
Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.
Costa, L. J., Lin, Y., Martin, T. G., Chhabra, S., Usmani, S. Z., Jagannath, S., Callander, N. S., Berdeja, J. G., Kang, Y., Vij, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.8030 · Cited by 10
Self-citationCreixenti, J. B., Mateos, M., Oriol, A., Larocca, A., Cavo, M., Rodríguez‐Otero, P., Leleu, X. P., Norkin, M., Nadeem, O., Hiemenz, J. W., et al. (2020) · Blood · doi:10.1182/blood-2020-137164 · Cited by 6
Self-citation
Cited by
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Self-citationElranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citation
Metadata
- Authors
- Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J. M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H., & Moreau, P.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Heidelberg (DE)
- Universitair Ziekenhuis Leuven (BE)
- Inserm (FR)
- Washington University in St. Louis (US)
- Nottingham University Hospitals NHS Trust (GB)
- Poznan University of Medical Sciences (PL)
- Ospedale Policlinico San Martino (IT)
- Centre Hospitalier Universitaire de Toulouse (FR)
- King's College London (GB)
- Universidad de Cantabria (ES)
- University of Cologne (DE)
- University of Turin (IT)
- University Medical Center Groningen (NL)
- Erasmus MC Cancer Institute (NL)
- Janssen (Germany) (DE)
- Janssen (France) (FR)
- Janssen (Belgium) (BE)
- Janssen Research & Development (United States) (US)
- Legend Biotech (United States) (US)
- Universitätsklinikum Würzburg (DE)
- Nantes Université (FR)
- ORCID
- Mateos, Maria-Victoria
- Weisel, Katja
- De Stefano, Valerio
- Goldschmidt, Hartmut
- Mohty, Mohamad
- Cavo, Michele
- Vij, Ravi
- Dytfeld, Dominik
- Angelucci, Emanuele
- Perrot, Aurore
- Benjamin, Reuben
- Ocio, Enrique M.
- Scheid, Christof
- Gay, Francesca
- Roeloffzen, Wilfried
- Broijl, Annemiek
- Schecter, Jordan M.
- Vogel, Martin
- San-Miguel, Jesus
- Sonneveld, Pieter
- Einsele, Hermann
- Moreau, Philippe
- Venue
- Leukemia
- Published
- 2022-03-24
- Volume
- 36
- Issue
- 5
- Pages
- 1371-1376
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC9061296
- OpenAlex
- W4221027512
- Cited by
- 252
- References
- 10
- Citations by year
- 2026: 38 · 2025: 63 · 2024: 77 · 2023: 56 · 2022: 17
- FWCI
- 38.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Leukemia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- relapsed/refractory multiple myeloma, standard of care, proteasome inhibitors, immunomodulators, anti-CD38 monoclonal antibody, real-world treatment patterns, progression-free survival, overall survival, treatment-emergent adverse events, heavily pretreated patients
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Multiple Myeloma, Prospective Studies, Standard of Care, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. https://app.cochat.ai/papers/10.1038/s41375-022-01531-2
- The paper
- Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., . . . Moreau, P. (2022). LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-022-01531-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.